CD46 and prostate carcinoma: We identified a novel human antibody YS5 that binds to a tumor-selective CD46 epitope with negligible binding to normal healthy tissues except for placenta trophoblasts and to a lesser degree the prostate epithelium, opening the door for therapeutic targeting of CD46 that is overexpressed in prostate cancer and a variety of other malignancies.